TY - JOUR
T1 - Serum test for assessing patients with Bence Jones Myeloma
AU - Bradwell, Arthur
AU - Carr-Smith, HD
AU - Mead, Graham
AU - Harvey, Timothy
AU - Drayson, Mark
PY - 2003/1/1
Y1 - 2003/1/1
N2 - Bence Jones protein in urine (immunoglobulin free-light-chains) is characteristic of light-chain multiple myeloma. We aimed to compare a quantitative immunoassay for serum free-light-chains with urine tests. Of 224 patients with light-chain myeloma tested at entry to clinical trials, all were correctly identified from serum samples. During monitoring of 82 patients, changes, in serum and urine tree-light-chains corresponded, but urine became negative for free-light-chains in 26 patients, whereas it remained abnormal in serum in 73 patients. Serum assays could replace Bence Jones protein urine tests for patients with light-chain multiple myeloma.
AB - Bence Jones protein in urine (immunoglobulin free-light-chains) is characteristic of light-chain multiple myeloma. We aimed to compare a quantitative immunoassay for serum free-light-chains with urine tests. Of 224 patients with light-chain myeloma tested at entry to clinical trials, all were correctly identified from serum samples. During monitoring of 82 patients, changes, in serum and urine tree-light-chains corresponded, but urine became negative for free-light-chains in 26 patients, whereas it remained abnormal in serum in 73 patients. Serum assays could replace Bence Jones protein urine tests for patients with light-chain multiple myeloma.
UR - http://www.scopus.com/inward/record.url?scp=0037425774&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(03)12457-9
DO - 10.1016/S0140-6736(03)12457-9
M3 - Article
C2 - 12583950
SN - 1474-547X
VL - 361
SP - 489
EP - 491
JO - Lancet
JF - Lancet
IS - 8
ER -